Inovio Pharmaceuticals reported Friday the positive long-term effects of its VGX-3100 vaccine, designed to treat cervical dysplasia and cancer caused by the human papillomavirus, or HPV.
ImmunoCellular Therapeutics has expanded the number of sites for its phase two clinical trial ofa potential vaccine treatment for brain cancer.
OXiGENE shares rose in pre-market trading Monday
Emergent BioSolutions has acquired the rights to Zanolimumab, an investigational and late-stage antibody cancer therapy.
ImmunoCellular Therapeutics will present positive results from a phase 1 clinical study on its ICT-107 therapy, a treatment for a type of brain tumor.